Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Nutritionals feed Abbott

This article was originally published in The Tan Sheet

Executive Summary

Nutritional sales grew 11 percent in the fourth quarter to $1.28 billion globally, with U.S. revenues climbing nearly 7 percent driven by the launch of infant formula Similac Advanced EarlyShield and continued sales of Glucerna and Ensure. International nutrition sales rose 15 percent, the Abbott Park, Ill.-based firm said Jan. 21. To address increased demand in Asia, where consumers are shaken by the contaminated formula scandal that rocked China in 2008, Abbott will open a manufacturing facility in Singapore this quarter, Investor Relations VP John Thomas said during a same-day earnings call. He also said the firm expects its planned acquisition of Advanced Medical Optics to grow its market share more than $4 billion globally with help from sales of the Tecnis multifocal intraocular lens FDA approved Jan. 16 (1"The Tan Sheet" Jan. 19, 2009, p. 17). Abbott's net sales in the quarter advanced 10.1 percent to $8 billion and for the year revenues grew 13.9 percent to $29.5 billion

You may also be interested in...



Abbott Nutrition Offers Complete Package For Similac Formula Users

Abbott Nutrition's innovative packaging for its Similac line of infant formulas shows the company empathizes with consumer's interests and needs, according to a leading industrial designer

Abbott Targets Diversity, Reels In Advanced Medical Optics For $2.8 Billion

Drug, device and nutritional maker Abbott is betting that its $2.8 billion purchase of laser vision correction, contact lens care and cataract surgery product maker Advanced Medical Optics will pay off once the economy recovers

MagGenome On Path To Nanoparticle Adjuvant, Founder Seeks Investment Opportunities

MagGenome, an Indian biotech which develops magnetic nanoparticle-based products for therapeutics and molecular diagnostics, is in the early research stage for a nanoparticle-based adjuvant for vaccines. Scrip spoke to founder Sam Santhosh and CEO and chief scientific officer C N Ramchand to gauge the enabling environment being created in India for cell and gene therapies, among other topics, in this wide-ranging audio interview. 

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS102540

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel